复方虎杖散颗粒联合盐酸伐昔洛韦片治疗女性生殖器疱疹的疗效观察

摘要

目的:探讨复方虎杖散颗粒联合盐酸伐昔洛韦片在治疗女性生殖器疱疹中的临床疗效,并初步探讨复方虎杖散颗粒在治疗女性生殖器疱疹中的作用机理.方法:以84例2015年6月至2016年6月期间于本院就诊治疗女性生殖器疱疹的患者资料作为研究资料,按治疗方案分为单一用药组(41例)和联合用药组(41例),单一用药组给予盐酸伐昔洛韦片口服治疗,联合用药组在给予盐酸伐昔洛韦片口服治疗基础上联合复方虎杖散颗粒治疗,对比分析患者治疗后生殖器疱疹改善情况、近期临床疗效、抗复发性疗效以及免疫学相关因子改善情况.结果:联合用药组患者治疗后生殖器疱疹止疱时间、结痂时间、疱疹消失时间、皮损愈合时间和疾愈时间均明显短于单一用药组(P＜0.05);治疗1个疗程后,联合用药组患者治疗总有效率为97.67％,显著高于常规疗法组的90.24％;患者结束用药6个月内,联合用药组患者治疗总有效率为93.02％,显著高于常规疗法组的65.85％;患者结束用药6个月内,联合用药组患者治疗总有效率为93.02％,显著高于常规疗法组的65.85％.治疗后联合用药组的外周血IL-2和IFN-γ检测水平分别为(324.62±28.54) mol/L和(331.42±24.83) mol/L,显著高于单一用药组的(287.49±21.53) mol/L和(279.81 ±22.49) mol/L,比较差异均具有统计学意义(P＜0.05).结论:复方虎杖散颗粒联合盐酸伐昔洛韦片可有效改善生殖器疱疹症状,提升治疗总有效率,降低治疗复发率,并能有效改善患者免疫功能,可作为治疗女性生殖器疱疹的有效方案.%Objectives:To study the curative effect of complex giant knotweed powder panicles joint valacyclovir hydrochloride for female genital herpes,and preliminary explore the functional mechanism.Methods:The 84 female patients with genital herpes in our hospital from June 2015 to June 2016 were selected and according to the treatment were divided into simple treatment group (n =41) and the joint treatment group (n =41).The simple treatment group was given only valacyclovir hydrochloride while the joint treatment group received additionally complex giant knotweed powder particles.The improvements in symptoms,recent clinical curative effect,recurrent curative effect and improvements in immunology related factors were all compared between the two groups.Results:The scabby time,herpes disappear time and skin lesion healing time and disease healing time in the joint treatment group after treatment were significantly shorter than those in the simple treatment group (P ＜ 0.05).After a course of treatment,the total effective rate in the joint treatment group was 97.67％,significantly higher than that of simple treatment group of 90.24％.At 6 months after treatment,the total effective rate in the joint treatment group was 93.02％,significantly higher than that of simple treatment group of 65.85％.The IL-2 and IFN-gamma levels in peripheral blood were 324.62-± 28.54 mol/L and 331.42 ± 24.83 mol/L in the joint treatment group after treatment,significantly higher than those of simple treatment group,which were 287.49 ± 21.53 and 21.53 ± 22.49,with statistically significant difference (P ＜ 0.05).